Maze Therapeutics navigates $190M financing round as it plots course to the clinic

Fierce 15 winner Maze Therapeutics just added $190 million to its fundraising pile in time to help its lead candidate, MZE001, make a clinical debut.

Maze wrapped up the fundraising round on Monday. Alongside news of the raise, the company unveiled plans to push its MZE001 program, which Maze is working on in Pompe disease, into the clinic in the first half of 2022.